Drug Trial Radar · NCT02231749
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Last checked: Nov 19, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,096
Actual
Start
Oct 16, 2014
Primary completion
Jun 26, 2017
Study completion Mar 21, 2025
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- Ono Pharmaceutical Co., Ltd.
- First posted
- Sep 4, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.
Conditions
- Advanced Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
Interventions
NivolumabBiological
IpilimumabBiological
SunitinibDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) in Intermediate/Poor Risk Participants Per Independent Radiology Review Committee (IRRC) Using RECIST v1.1Time frame: From first dose until date of documented disease progression or subsequent therapy, whichever occurs first (assessed up to June 2017, approximately 31 months)
- Overall Survival (OS) in Intermediate/Poor-Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)Time frame: From the date of randomization to the date of death (assessed up to June 2017, approximately 31 months)
- Progression-Free Survival (PFS) in Intermediate/Poor-Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)Time frame: From date of first dose to date of documented disease progression or death due to any cause, whichever occurs first (assessed up to June 2017, approximately 31 months)
Locations
189 sites in 28 countries. Site status is shown where the registry gives one.
Local Institution - 0006
Duarte, California
Local Institution - 0057
La Jolla, California
Local Institution - 0044
Los Angeles, California
Local Institution - 0035
Los Angeles, California
Local Institution - 0067
Stanford, California
Local Institution - 0138
New Haven, Connecticut
Local Institution - 0034
Washington D.C., District of Columbia
Local Institution - 0049
Tampa, Florida
Local Institution - 0068
Atlanta, Georgia
Local Institution - 0038
Indianapolis, Indiana
Local Institution - 0042
Iowa City, Iowa
Local Institution - 0163
Fairway, Kansas
Local Institution - 0048
Baltimore, Maryland
Local Institution - 0004
Baltimore, Maryland
Local Institution - 0135
Boston, Massachusetts
Local Institution - 0110
Boston, Massachusetts
Local Institution - 0161
Boston, Massachusetts
Local Institution - 0173
Boston, Massachusetts
Local Institution - 0046
Ann Arbor, Michigan
Local Institution - 0043
Detroit, Michigan
Local Institution - 0036
Buffalo, New York
Local Institution - 0001
New York, New York
Local Institution - 0008
Charlotte, North Carolina
Local Institution - 0045
Durham, North Carolina
Local Institution - 0007
Cleveland, Ohio
Local Institution - 0164
Columbus, Ohio
Local Institution - 0039
Portland, Oregon
Local Institution - 0054
Allentown, Pennsylvania
Local Institution - 0005
Philadelphia, Pennsylvania
Local Institution - 0031
Pittsburgh, Pennsylvania
Local Institution - 0055
Charleston, South Carolina
Local Institution - 0159
Chattanooga, Tennessee
Local Institution - 0066
Nashville, Tennessee
Local Institution - 0056
Dallas, Texas
Local Institution - 0032
Dallas, Texas
Local Institution - 0003
Houston, Texas
Local Institution - 0041
Seattle, Washington
Local Institution - 0097
CABA, Argentina
Local Institution - 0100
Córdoba, Argentina
Local Institution - 0099
Berazategui, Buenos Aires, Argentina
Showing 40 of 189 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.